[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Shiba M, Takatera H, Tokizane T, Terakawa T: [Angiosarcoma of the spleen 11 years after chemotherapy for testicular seminoma: a case report]. Hinyokika Kiyo; 2003 Aug;49(8):463-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiosarcoma of the spleen 11 years after chemotherapy for testicular seminoma: a case report].
  • A 32-year-old man who had previously undergone chemotherapy for testicular seminoma 11 years ago was admitted to our hospital with a pain in the right leg.
  • Computed tomography (CT) and bone scintigraphy revealed splenomegaly and multiple bone disease.
  • The pathologic diagnosis of the resected spleen and the biopsied rib was angiosarcoma.
  • We found no reports of angiosarcoma following previous chemotherapy for testicular cancer.
  • It is unclear whether the angiosarcoma is a secondary neoplasm induced by the chemotherapy or not.
  • The chemotherapy might also have affected the chromosomal aberration presumably in endothelial progenitor cells causing the development of a secondary neoplasm.
  • To our knowledge, this is the first case of angiosarcoma after chemotherapy for testicular seminoma.
  • [MeSH-major] Hemangiosarcoma / etiology. Neoplasms, Second Primary / etiology. Seminoma / drug therapy. Splenic Neoplasms / etiology. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chromosome Aberrations. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518382.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Asmane I, Litique V, Heymann S, Marcellin L, Métivier AC, Duclos B, Bergerat JP, Kurtz JE: Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature. Anticancer Res; 2008 Sep-Oct;28(5B):3041-5
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature.
  • Angiosarcoma represents 1 to 2% of soft tissue tumors.
  • The outcome of angiosarcoma is poor for those patients in whom aggressive surgery cannot be considered.
  • Chemotherapy, generally consisting of the combination of anthracyclines and ifosfamide, has little, but consistent effect.
  • We report three cases of angiosarcoma in which first-line chemotherapy with adriamycin 40 mg/m2 day 1, ifosfamide 3 g/m2 day 1-2, cisplatin 35 mg/m2 day 1-2 and paclitaxel 175 mg/m2 day 3 led to clinically meaningful responses.
  • The clinical relevance of incorporating paclitaxel in conventional soft tissue chemotherapy schedules in the light of both literature data and our experience is discussed.
  • We emphasize the need for designing trials specifically dedicated to angiosarcomas, as this rare and severe condition may be a target for new antiangiogenic drugs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Hemangiosarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031953.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


3. Chun R, Kurzman ID, Couto CG, Klausner J, Henry C, MacEwen EG: Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study. J Vet Intern Med; 2000 Sep-Oct;14(5):495-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study.
  • Sixteen dogs with histologically confirmed appendicular osteosarcoma were treated by amputation followed by cisplatin and doxorubicin chemotherapy.
  • All dogs began chemotherapy within 24 hours of surgery.
  • Thoracic radiography was performed every 2 months after completion of therapy to monitor for metastatic disease.
  • Two dogs were still alive and free from disease at the time of last contact (24 and 75 months, respectively).
  • Of the remaining 5 dogs, euthanasia was performed because of complications of idiopathic megaesophagus (n = 1), arthritis (n = 2), and hemangiosarcoma (n = 2).
  • The median disease-free interval and survival times were 15.7 and 18 months, respectively.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11012111.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Gatcombe HG, Olson TA, Esiashvili N: Metastatic primary angiosarcoma of the breast in a pediatric patient with a complete response to systemic chemotherapy and definitive radiation therapy: case report and review of the literature. J Pediatr Hematol Oncol; 2010 Apr;32(3):192-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic primary angiosarcoma of the breast in a pediatric patient with a complete response to systemic chemotherapy and definitive radiation therapy: case report and review of the literature.
  • We present a case of a rare malignancy, primary breast angiosarcoma, in a 15-year-old girl.
  • The patient was treated with systemic chemotherapy and definitive radiation therapy to her left breast and achieved a complete response.
  • She has no evidence of disease recurrence 44 months from her initial diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Breast Neoplasms / therapy. Hemangiosarcoma / therapy. Mediastinal Neoplasms / therapy. Radiotherapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Magnetic Resonance Imaging. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186104.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Yilmazlar T, Kirdak T, Adim S, Ozturk E, Yerci O: A case of hemangiosarcoma in thyroid with severe anemia due to bone marrow metastasis. Endocr J; 2005 Feb;52(1):57-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of hemangiosarcoma in thyroid with severe anemia due to bone marrow metastasis.
  • Postoperative histopathological examination of the specimen revealed hemangiosarcoma of the thyroid.
  • After establishment of the diagnosis chemotherapy was started.
  • But hemoglobin values decreased again and hepatosplenomegaly developed at the second month of surgery.
  • Bone marrow aspiration cytology which was performed demonstrated the same tumoral cells infiltrating bone marrow.
  • Thyroid hemangiosarcoma can metastasize to the bone marrow and anemia may be an indicator of the advanced disease.
  • In the differential diagnosis of the anemia, bone marrow metastasis and bone marrow biopsy should be considered in suspected cases.
  • [MeSH-major] Anemia / etiology. Bone Marrow Neoplasms / complications. Bone Marrow Neoplasms / secondary. Hemangiosarcoma / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Blood Transfusion. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15758558.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Scholsem M, Raket D, Flandroy P, Sciot R, Deprez M: Primary temporal bone angiosarcoma: a case report. J Neurooncol; 2005 Nov;75(2):121-5
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary temporal bone angiosarcoma: a case report.
  • We present a rare case of temporal bone angiosarcoma diagnosed in a 26-year-old female patient at 36 week of pregnancy.
  • Cranial imaging studies showed a 7 x 5 x 4 cm hypervascularized mass located in the left middle fossa with lysis of the temporal bone and extension to the subcutis.
  • Pathological findings were those of a poorly differentiated, highly malignant sarcoma with a large epitheloid component and immunohistochemical evidence of endothelial differentiation (CD31, Factor VIII related antigen, CD34), consistent with an angiosarcoma with epitheloid features.
  • The patient received adjuvant radiotherapy followed by a course of chemotherapy consisting of 6 cycles of paclitaxel.
  • At 15 months follow-up, she developed multiple distant metastasis to a left postauricular lymph node and to the lungs and ribs.
  • The patient was given a second line chemotherapy using doxorubicine and ifosfamide.
  • Despite an initial good response, she died with metastatic disease 26 months after diagnosis.
  • We present a rare case of primary temporal bone angiosarcoma and report our experience with a multimode therapeutic approach combining surgery, radiotherapy and chemotherapy.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Skull Neoplasms / diagnosis. Skull Neoplasms / pathology. Temporal Bone
  • [MeSH-minor] Adult. Angiography. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Combined Modality Therapy. Fatal Outcome. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Pregnancy. Pregnancy Trimester, Third. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 1948 Mar;57(1):235-40 [18913539.001]
  • [Cites] Cancer. 1971 Jun;27(6):1403-14 [5088217.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):73-6 [2045922.001]
  • [Cites] Laryngoscope. 1974 Mar;84(3):454-8 [4814415.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):755-8 [11290494.001]
  • [Cites] Am J Otolaryngol. 1999 Jul-Aug;20(4):223-31 [10442774.001]
  • [Cites] Surg Neurol. 2004 Jun;61(6):575-9 [15165804.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):727-36 [7198934.001]
  • [Cites] Neurosurgery. 1999 Feb;44(2):405-7; discussion 407-8 [9932897.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):989-96 [7842420.001]
  • [Cites] Cancer Invest. 1998;16(7):442-6 [9774950.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Feb;103(2):156-9 [8311392.001]
  • [Cites] J Laryngol Otol. 1980 Feb;94(2):205-10 [7189541.001]
  • [Cites] South Med J. 1991 Apr;84(4):517-20 [2014445.001]
  • [Cites] Eur J Neurol. 2003 Nov;10(6):741-2 [14641524.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):583-5; discussion 585-6 [8837814.001]
  • [Cites] Histopathology. 1991 May;18(5):395-402 [1715839.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1997 May 4;40(1):67-71 [9184980.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17 (10 ):1946-8 [8933884.001]
  • [Cites] Pediatr Radiol. 1992;22(2):134-5 [1501943.001]
  • (PMID = 16132518.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Kudva R, Perveen S, Janardhana A: Primary epithelioid angiosarcoma of bone: a case report with immunohistochemical study. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):811-3
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary epithelioid angiosarcoma of bone: a case report with immunohistochemical study.
  • Primary malignant vascular tumors of the bone are exceedingly rare and represent <1% of primary malignant bone tumors.
  • Angiosarcoma is a malignant mesenchymal neoplasm in which the neoplastic cells demonstrate endothelial differentiation.
  • Epithelioid angiosarcoma (EA) is a rare variant of angiosarcoma that is characterized by large cells with an epithelioid morphology.
  • He was treated with amputation and chemotherapy.
  • After 1 month of chemotherapy, he developed pleural effusion and died.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Hemangiosarcoma / diagnosis. Hemangiosarcoma / pathology. Sarcoma / diagnosis. Sarcoma / pathology. Tibia / pathology
  • [MeSH-minor] Amputation. Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Drug Therapy / methods. Fatal Outcome. Histocytochemistry. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Microscopy. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045426.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents
  •  go-up   go-down


8. Wang C, Rabah R, Blackstein M, Riddell RH: Bone marrow metastasis of angiosarcoma. Pathol Res Pract; 2004;200(7-8):551-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow metastasis of angiosarcoma.
  • We report a rare finding of bone marrow metastasis from an angiosarcoma.
  • The patient was a 36-year-old man who initially presented with a high-grade angiosarcoma of the spleen and was treated with splenectomy and chemotherapy.
  • He developed leukoerythroblastic anemia three years after splenectomy.
  • Bone marrow biopsy revealed extensive infiltrate by angiosarcoma with typical features of spindle tumor cells and anastomosing vascular channels.
  • Although metastases occur commonly, bone marrow findings have been rarely documented.
  • We have found in the literature two other cases of bone marrow metastasis of angiosarcoma, and all these patients had a primary tumor of the spleen.
  • It would seem that splenic angiosarcomas have a virtually unique propensity for infiltration in the bone marrow.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Hemangiosarcoma / secondary. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15462503.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / von Willebrand Factor
  • [Number-of-references] 10
  •  go-up   go-down


9. Saglik Y, Yildiz Y, Atalar H, Basarir K: Primary angiosarcoma of the fibula : a case report. Acta Orthop Belg; 2007 Dec;73(6):799-803
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary angiosarcoma of the fibula : a case report.
  • Primary vascular neoplasms of bone are rare and have a poor prognosis.
  • Angiosarcoma of bone originates in vascular endothelial cells within bone tissue.
  • Patients may present with unifocal or multifocal osseous disease.
  • Here we present a 72-year-old male patient who had primary angiosarcoma of the fibula.
  • He was treated with amputation, and the metastases that later emerged were successfully managed with chemotherapy.
  • [MeSH-major] Bone Neoplasms / diagnosis. Fibula. Hemangiosarcoma / diagnosis
  • [MeSH-minor] Aged. Amputation. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260498.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


10. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, Hogendoorn PC, Marreaud S, Van Glabbeke M, Blay JY: Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer; 2008 Nov;44(16):2433-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.
  • RATIONALE: Angiosarcomas of soft tissue represent a heterogenous group of rare sarcomas with specific clinical behaviour and risk factors.
  • Paclitaxel appears to induce tumour control in a higher proportion of patients with angiosarcoma, as compared to other sarcomas.
  • METHOD: Clinical data from patients with angiosarcomas of soft tissue treated with single agent paclitaxel were collected from the centres of the soft tissue and bone sarcoma group of EORTC, using a standardised data collection form.
  • Thirteen (40%) patients had been pretreated with doxorubicin-based first-line-chemotherapy and three of them (9%) had also received second-line chemotherapy with ifosfamide.
  • Eleven (34%) patients had been irradiated before as treatment for angiosarcoma.
  • In 8 (25%) patients, the angiosarcoma occurred at sites of prior radiation therapy for other malignancies.
  • The median time to progression was 7.6 months (range, 1-42) for the whole group.
  • CONCLUSION: Paclitaxel was found to be an active agent in angiosarcoma of soft tissue in this retrospective analysis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Hemangiosarcoma / drug therapy. Paclitaxel / therapeutic use. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Facial Neoplasms / drug therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retrospective Studies. Scalp. Skin Neoplasms / drug therapy. Young Adult


11. Mittal S, Goswami C, Kanoria N, Bhattacharya A: Post-irradiation angiosarcoma of bone. J Cancer Res Ther; 2007 Apr-Jun;3(2):96-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-irradiation angiosarcoma of bone.
  • Radiation therapy is extensively used for treatment of malignancies, but angiosarcomas occurring in an irradiated area are uncommon.
  • We report a rare case of high-grade epithelioid angiosarcoma of upper end of right humerus in a 67-year-old male occurring ten years following irradiation for giant cell tumor of the same anatomical site.
  • He underwent excision of affected part of humerus followed by cemented hemiarthroplasty and bone grafting.
  • After initial histopathological diagnostic dilemma the final report was given as post-radiation angiosarcoma.
  • He received four cycles of combination chemotherapy with doxorubicin and ifosfamide and currently is free of recurrence after six months follow-up.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Humerus. Neoplasms, Radiation-Induced / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998731.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


12. Yau T, Leong CH, Chan WK, Chan JK, Liang RH, Epstein RJ: A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO). Cancer Chemother Pharmacol; 2008 Apr;61(4):717-20
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO).
  • Here we report an unusual case of mixed Wilms' tumour and angiosarcoma in a 38-year-old female patient who presented with haematuria and right lower back pain.
  • Histopathology revealed differentiated adult Wilms' tumour with renal angiosarcoma, whereas the pathology of the para-aortic lymph node and bone metastasis revealed angiosarcoma only.
  • In view of her cachexia and cytopaenia, emergency chemotherapy was initiated using a modified regimen of carboplatin, etoposide and vincristine (CEO) in preference to the more traditional but less well-tolerated VAC (vincristine, actinomycin D, cyclophosphamide).
  • This case suggests that highly angiogenic tumours such as angiosarcoma may be effectively palliated using agents usually reserved for refractory Wilms' tumour, and supports the view that adult Wilms' tumour is more sensitive to such agents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemangiosarcoma / drug therapy. Kidney Neoplasms / drug therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carboplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis. Neoplasm Recurrence, Local. Platelet Count. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571263.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Tada Y, Takiguchi Y, Terada J, Yoshida T, Shinozaki A, Sakao S, Kasahara Y, Kurosu K, Tanabe N, Tatsumi K, Hiroshima K, Kuriyama T: [A case of angiosarcoma of pelvis with pulmonary metastases which responded to paclitaxel]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2275-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of angiosarcoma of pelvis with pulmonary metastases which responded to paclitaxel].
  • Bone scintigram and MRI revealed multiple osteolytic lesions in pelvis and lumbar spine.
  • Biopsy of the bone lesion established a diagnosis of angiosarcoma.
  • Chemotherapy with paclitaxel and palliative radiotherapy for the bone were initiated.
  • Pulmonary metastases dramatically diminished after 4 courses of paclitaxel treatment.
  • Salvage chemotherapy of weekly administration of docetaxel yielded limited effects.
  • The patient died of cancer one year after treatment initiation.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Bone Neoplasms / drug therapy. Hemangiosarcoma / drug therapy. Lung Neoplasms / secondary. Paclitaxel / therapeutic use. Pelvic Bones
  • [MeSH-minor] Humans. Male. Middle Aged. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079629.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Kawashima H, Ishikawa S, Fukase M, Ogose A, Hotta T: Successful surgical treatment of angiosarcoma of the spine: a case report. Spine (Phila Pa 1976); 2004 Jul 1;29(13):E280-3
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful surgical treatment of angiosarcoma of the spine: a case report.
  • OBJECTIVES: To report primary angiosarcoma of the T8 vertebra, which was successfully managed with en bloc spondylectomy and postoperative chemotherapy.
  • SUMMARY OF BACKGROUND DATA: To the best of our knowledge, the present case is the first documented example of successful treatment of angiosarcoma of the spine.
  • METHODS: Angiosarcoma of the eighth thoracic vertebra was diagnosed in a 48-year-old man with impending neurologic deficit.
  • The histologic diagnosis of the excised specimen was high-grade angiosarcoma.
  • Postoperative chemotherapy was implemented to prevent local recurrence and distant metastasis.
  • CONCLUSION: This case is the first documented example of successful treatment of angiosarcoma of the thoracic spine.
  • Radiologic findings were nonspecific; consequently, correct diagnosis was established by pathologic examination.
  • Immediate, aggressive operative treatment and postoperative adjuvant chemotherapy afforded a satisfactory outcome.
  • [MeSH-major] Hemangiosarcoma / surgery. Spinal Neoplasms / surgery. Thoracic Vertebrae / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Back Pain / etiology. Bone Screws. Bone Substitutes / therapeutic use. Calcium Compounds. Ceramics. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Durapatite. Etoposide / administration & dosage. Follow-Up Studies. Humans. Hypesthesia / etiology. Ifosfamide / administration & dosage. Internal Fixators. Male. Middle Aged. Osteolysis / etiology. Prostheses and Implants. Prosthesis Implantation. Remission Induction. Silicates. Spinal Cord Compression / etiology

  • Hazardous Substances Data Bank. CALCIUM COMPOUNDS .
  • Hazardous Substances Data Bank. HYDROXYAPATITE .
  • Hazardous Substances Data Bank. Calcium silicate .
  • Hazardous Substances Data Bank. WOLLASTONITE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15223950.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Substitutes; 0 / Calcium Compounds; 0 / Silicates; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 91D9GV0Z28 / Durapatite; S4255P4G5M / calcium silicate; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA, Mankin HJ, Kirsch DG, Rosenberg AE, Nielsen GP, Desphpande V, Suit HD, DeLaney TF, Yoon SS: Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol; 2007 Jun;14(6):1953-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcome of 82 patients with angiosarcoma.
  • BACKGROUND: Angiosarcomas are an uncommon type of malignancy that are generally thought to behave usually in a locally aggressive fashion; they often metastasize to distant sites.
  • METHODS: Patients with a diagnosis of angiosarcoma treated at our institution between 1980 and 2006 were analyzed for patient demographics, tumor characteristics, multimodality treatment, and outcomes.
  • Tumors were located throughout the body: 32 cutaneous, 22 deep soft tissues or organs, 10 radiation or lymphedema field, 8 bone, and 7 nonirradiated breast.
  • Of 46 patients with primary disease, all patients underwent surgical resection, 67% received radiotherapy, and 27% received chemotherapy.
  • Of 36 patients with advanced disease, 36% underwent a palliative operation, 78% received radiation, and 58% received chemotherapy.
  • The role of adjuvant chemotherapy is unclear.
  • Patients with advanced disease have a poor prognosis, but there can be dramatic responses to chemotherapy in a minority of patients.
  • [MeSH-major] Hemangiosarcoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / pathology. Bone Neoplasms / surgery. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / surgery. Palliative Care. Radiotherapy, Adjuvant. Retrospective Studies. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356953.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5K12CA87723-03
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Batzios S, Michalopoulos A, Kaklamanis L, Stathopoulos J, Christopoulou M, Koutantos J, Stathopoulos GP: Angiosarcoma of the heart: case report and review of the literature. Anticancer Res; 2006 Nov-Dec;26(6C):4837-42
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the heart: case report and review of the literature.
  • BACKGROUND: Primary angiosarcoma of the heart is an extremely rare malignant disease.
  • PATIENTS AND METHODS: A 32-year-old female with primary angiosarcoma of the heart at an advanced stage with lung and bone metastases is presented.
  • Chemotherapy (cisplatin, epirubicin and ifosfamide) was administered.
  • CONCLUSION: This case of angiosarcoma of the heart is presented because of the extreme rarity of this disease, and its responsiveness to chemotherapy in combination with imatinib and herceptin.
  • [MeSH-major] Heart Neoplasms / pathology. Hemangiosarcoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Cisplatin / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Lung Neoplasms / secondary

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214349.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


17. Nascimento AF, Raut CP, Fletcher CD: Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol; 2008 Dec;32(12):1896-904
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic.
  • Mammary angiosarcoma is a rare neoplasm, accounting for about 0.05% of all primary malignancies of the breast.
  • Forty-nine cases of primary angiosarcoma of the breast were retrieved from our files.
  • Two patients had a history of prior radiation treatment for breast carcinoma.
  • Forty-six patients were treated surgically, 11 underwent chemotherapy, and 12 patients received radiotherapy.
  • Ten patients (24.4%) showed evidence of local recurrence within 11 to 60 months (median 36) after diagnosis.
  • Twenty-four patients (58.5%) thus far have developed metastases, which were most commonly to lung, liver, skin, and bone.
  • Time interval between diagnosis and metastasis ranged from 2 to 144 months (median 34).
  • In conclusion, mammary angiosarcoma is a rare disease that affects relatively younger patients.
  • This tumor seems to have an overall similar clinical course as other types of angiosarcoma arising in skin or soft tissue; it carries a moderate risk of local recurrence, and a high risk of metastasis and death.
  • [MeSH-major] Breast Neoplasms / pathology. Hemangiosarcoma / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813119.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Deutsch M, Wollman MR: Radiotherapy for metastases to the mandible in children. J Oral Maxillofac Surg; 2002 Mar;60(3):269-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six children had a neuroblastoma, 1 had angiosarcoma of the liver, 1 had adenocarcinoma of the rectum, and 1 had peripheral primitive neuroectodermal tumor (Ewing's sarcoma) of the spine.
  • In 3 children, the mandible was the first bone involved by metastases.
  • All children had received chemotherapy.
  • RESULTS: All children died of disseminated disease at 5 to 59 months from their initial diagnosis, 5 to 29 months from the detection of metastases to bone, and only 6 days to 17 months (median, 2 months) from the first treatment of metastases to the mandible.
  • CONCLUSIONS: The outlook for children with metastases that involve the mandible is very poor, and we recommend short intensive courses of radiotherapy consisting of 1 to 3 treatments to total doses of 400 to 1,200 cGy for palliation of pain.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adolescent. Child. Child, Preschool. Female. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / secondary. Humans. Infant. Liver Neoplasms / pathology. Male. Neuroblastoma / radiotherapy. Neuroblastoma / secondary. Pain, Intractable / radiotherapy. Radiotherapy Dosage. Rectal Neoplasms / pathology. Retrospective Studies. Sarcoma, Ewing / radiotherapy. Sarcoma, Ewing / secondary. Spinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Association of Oral and Maxillofacial Surgeons
  • (PMID = 11887137.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Liptak JM, Kamstock DA, Dernell WS, Monteith GJ, Rizzo SA, Withrow SJ: Oncologic outcome after curative-intent treatment in 39 dogs with primary chest wall tumors (1992-2005). Vet Surg; 2008 Jul;37(5):488-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic outcome after curative-intent treatment in 39 dogs with primary chest wall tumors (1992-2005).
  • OBJECTIVE: To describe the clinical features and determine oncologic outcome and prognostic factors for dogs with primary tumors of the osseous chest wall.
  • Signalment, preoperative clinical features, reconstruction technique, and oncologic outcome (local tumor recurrence, metastasis, and survival time) were determined from medical records and by telephone contact with owners and referring veterinarians.
  • Logistic regression was used to determine if increased serum alkaline phosphatase (ALP) concentration was associated with tumor type.
  • RESULTS: Of the 39 dogs with tumors arising from the chest wall, 25 had osteosarcoma, 12 had chondrosarcoma, and 2 dogs had hemangiosarcoma.
  • Median survival time (MST) for dogs with rib osteosarcoma was 290 days.
  • MST for dogs with rib chondrosarcoma was not reached (mean 1301 days) and survival was significantly greater than all other types of rib tumors (P=.0321).
  • CONCLUSION: Rib tumors should be resected with wide margins to decrease the risk of incomplete excision, because local tumor recurrence has a significant impact on the survival time.
  • The prognosis for dogs with rib chondrosarcoma is very good, but guarded for other types of tumors.
  • Prognosis for dogs with primary rib chondrosarcoma is very good with surgery alone, but surgery and adjunctive chemotherapy is recommended for dogs with primary rib osteosarcoma and the prognosis remains guarded.
  • [MeSH-major] Bone Neoplasms / veterinary. Chondrosarcoma / veterinary. Dog Diseases / surgery. Hemangiosarcoma / veterinary. Osteosarcoma / veterinary. Thoracic Wall
  • [MeSH-minor] Alkaline Phosphatase / metabolism. Animals. Chemotherapy, Adjuvant / veterinary. Cohort Studies. Dogs. Female. Kaplan-Meier Estimate. Logistic Models. Male. Prognosis. Proportional Hazards Models. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18986317.001).
  • [ISSN] 1532-950X
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


20. Bürk J, Gerlach U, Baumann T, Langer M, Winterer JT: Epithelioid angiosarcoma of the scapula. In Vivo; 2010 Sep-Oct;24(5):783-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid angiosarcoma of the scapula.
  • Epithelioid angiosarcoma is a rare variation of an angiosarcoma and its localization in the bone is exceptionally infrequent.
  • This report presents the case of a 48-year-old male with an epithelioid angiosarcoma of the scapula.
  • In CT and MRI scans an inhomogeneous tumour with osseous destructions, lytic areas, central necrosis and marginal hyperperfusion was observed.
  • The tumour was treated initially with neoadjuvant chemotherapy, followed by dose escalation, peripheral blood stem cell transplantation and resection of the lesion.
  • [MeSH-major] Bone Neoplasms / pathology. Hemangiosarcoma / pathology. Sarcoma / pathology. Scapula / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Necrosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20952750.001).
  • [ISSN] 1791-7549
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Muzi MG, Rulli F, Federico F: Angiosarcoma of the spleen mimicking rupture. Case report and literature review. Acta Biomed Ateneo Parmense; 2000;71(5):135-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the spleen mimicking rupture. Case report and literature review.
  • Primary angiosarcoma of the spleen is very rare and only 143 cases have previously been reported.
  • Patients with or without metastatic disease may be treated by chemotherapy but with poor results.
  • Radiotherapy is used for the pain from bone metastasis.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Splenic Neoplasms / diagnosis. Splenic Rupture / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450114.001).
  • [Journal-full-title] Acta bio-medica de L'Ateneo parmense : organo della Società di medicina e scienze naturali di Parma
  • [ISO-abbreviation] Acta Biomed Ateneo Parmense
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 25
  •  go-up   go-down


22. Hsu JT, Chen HM, Lin CY, Yeh CN, Hwang TL, Jan YY, Chen MF: Primary angiosarcoma of the spleen. J Surg Oncol; 2005 Dec 15;92(4):312-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary angiosarcoma of the spleen.
  • BACKGROUND AND OBJECTIVES: Primary splenic angiosarcoma is a very rare and aggressive neoplasm with a high metastatic rate and dismal prognosis.
  • METHODS: The records of all cases of primary splenic angiosarcoma treated at Chang Gung Memorial Hospital from April 1991 to July 2004 were retrospectively reviewed.
  • Three patients had distant metastasis to the liver (n = 2), bone (n = 1), bone marrow (n = 1), and small bowel (n = 1) at diagnosis.
  • Liver (n = 3), bone (n = 1), and bone marrow (n = 1) metastases were found in four patients after initial therapy.
  • Five of the six cases underwent a splenectomy, one underwent partial hepatectomy, and one received chemotherapy.
  • The respective 1-, 3- and 5-year survival rates were 60%, 40%, and 40%, and the median survival time was 36 months.
  • CONCLUSIONS: The clinical presentations of splenic angiosarcoma were similar to those of previous reports apart from the higher rate of splenomegaly observed in this study.
  • [MeSH-major] Hemangiosarcoma. Splenic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16299797.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. López Cubillana P, Martínez Barba E, Server Pastor G, Prieto González A, Ferri Níguez B, Cao Avellaneda E, López López AI, Nicolás Torroalba JA, Rigabert Montiel M, Tornero Ruiz J, García Hernández JA, Gómez Gómez G, Martínez Pertusa P, Guardiola Mas A, Pérez Albacete M: [Fatal evolution of a renal angiosarcoma]. Arch Esp Urol; 2004 May;57(4):425-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fatal evolution of a renal angiosarcoma].
  • [Transliterated title] Evolución fatal de angiosarcoma renal.
  • OBJECTIVES: Report a new case of renal angiosarcoma treated by surgery and adjuvant chemotherapy with bad results.
  • Pathology reports renal angiosarcoma.
  • RESULTS: Three months after surgery patient refers lumbar pain and hemoptysis and CT scan reveals the existence of multiple bone and lung metastasis; a regimen of systemic chemotherapy with Doxorrubicine+ Ifosfamide was started without response; he died two months later.
  • CONCLUSIONS: Primary renal angiosarcoma is very rare, with less than 10 cases in the literature before 1998, and it is always associated with bad prognosis.
  • Diagnosis is based on immunohistochemical studies (antibodies against CD31, CD34 and factor VIII related antigen) to define the endothelial differentiation of the tumor.
  • There is no experience to define the best therapeutic strategy against this entity.
  • [MeSH-major] Hemangiosarcoma / therapy. Kidney Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15270285.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 3
  •  go-up   go-down


24. Rihova B: Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates. Adv Drug Deliv Rev; 2009 Nov 12;61(13):1149-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dox) containing an N-(2-hydroyxypropyl)methacrylamide copolymer carrier targeted with autologous or commercial human immunoglobulin in six patients aged 28-55 suffering from therapy-resistant metastatic cancer.
  • Four of six monitored patients attained stabilization of disease (liver ultrasound scan and bone computer tomography) with a very good quality of life lasting from seven up to 18 months.
  • Positive response to the treatment was, among others, evaluated as decreased CA 15-3 and CEA tumor markers.
  • In three of five tested patients the serum level of C-reactive protein was temporarily increased 72 h after the treatment.
  • [MeSH-minor] Acrylamides / chemistry. Adult. Animals. Biomarkers, Tumor / blood. Breast Neoplasms / drug therapy. Drug Carriers / chemistry. Drug Delivery Systems. Drug Resistance, Neoplasm. Female. Hemangiosarcoma / drug therapy. Humans. Immunoglobulins, Intravenous / administration & dosage. Immunoglobulins, Intravenous / immunology. Immunologic Factors / administration & dosage. Immunologic Factors / immunology. Middle Aged. Neoplasm Metastasis. Quality of Life. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682512.001).
  • [ISSN] 1872-8294
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Drug Carriers; 0 / Immunoglobulin G; 0 / Immunoglobulins, Intravenous; 0 / Immunologic Factors; 0 / Polymethacrylic Acids; 0 / doxorubicin-N-(2-hydroxypropyl)methacrylamide copolymer conjugate; 21442-01-3 / N-(2-hydroxypropyl)methacrylamide; 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin
  •  go-up   go-down


25. Hohenhaus AE: Transfusion issues in the cancer patient. Clin Tech Small Anim Pract; 2003 May;18(2):135-8
MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blood transfusions are a lifesaving but transient therapy used to correct deficiencies of blood cells and coagulation factors that occur in cancer patients.
  • Anemia can occur in cancer patients as a result of hemolysis, blood loss, or bone marrow failure.
  • The blood component most commonly recommended for the treatment of anemia is packed red blood cells.
  • Coagulation disorders are common with hemangiosarcoma and diffuse hepatic tumors.
  • Fresh frozen plasma is used as a source for replacement coagulation factors for the treatment of disseminated intravascular coagulation or other cancer-associated coagulopathies.
  • Although thrombocytopenia and neutropenia can be the result of bone-marrow failure from tumor infiltration, chemotherapy, or radiation therapy, these platelets and neutrophils are rarely transfused to veterinary cancer patients.
  • [MeSH-major] Anemia / veterinary. Blood Coagulation Disorders / veterinary. Blood Transfusion / veterinary. Cat Diseases / therapy. Dog Diseases / therapy. Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Bleeding Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12831078.001).
  • [ISSN] 1096-2867
  • [Journal-full-title] Clinical techniques in small animal practice
  • [ISO-abbreviation] Clin Tech Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down






Advertisement